A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast
出版年份 2016 全文链接
标题
A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast
作者
关键词
-
出版物
Expert Review of Clinical Immunology
Volume 12, Issue 3, Pages 237-249
出版商
Informa UK Limited
发表日期
2015-12-22
DOI
10.1586/1744666x.2016.1134319
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- New Drugs and Treatment Targets in Psoriasis
- (2015) K Kofoed et al. ACTA DERMATO-VENEREOLOGICA
- Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)
- (2015) C. Paul et al. BRITISH JOURNAL OF DERMATOLOGY
- Cytokines in psoriasis
- (2015) Jaymie Baliwag et al. CYTOKINE
- Emerging oral drugs for psoriasis
- (2015) Tahmina Mahmood et al. EXPERT OPINION ON EMERGING DRUGS
- Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis
- (2015) Hunar Abdulrahim et al. EXPERT OPINION ON PHARMACOTHERAPY
- Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial
- (2015) Diamant Thaçi et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)
- (2015) Kim Papp et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Psoriasis
- (2015) Wolf-Henning Boehncke et al. LANCET
- Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
- (2015) Christopher E M Griffiths et al. LANCET
- Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity
- (2014) P.H. Schafer et al. CELLULAR SIGNALLING
- Drug therapies in dermatology
- (2014) A. Aslam et al. CLINICAL MEDICINE
- Prevalence of psoriatic arthritis in psoriasis patients according to newer classification criteria
- (2014) Hernán Maldonado Ficco et al. CLINICAL RHEUMATOLOGY
- Clinical and Molecular Genetics of the Phosphodiesterases (PDEs)
- (2014) Monalisa F. Azevedo et al. ENDOCRINE REVIEWS
- Role of IL-23 in the pathogenesis of psoriasis: a novel potential therapeutic target?
- (2014) Andrea Chiricozzi et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- PASI90 response: the new standard in therapeutic efficacy for psoriasis
- (2014) L. Puig JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registry
- (2014) G. Carretero et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials
- (2014) Richard G. Langley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cyclic Nucleotide Phosphodiesterases: important signaling modulators and therapeutic targets
- (2014) F Ahmad et al. ORAL DISEASES
- Psoriasis
- (2014) P. Di Meglio et al. Cold Spring Harbor Perspectives in Medicine
- Novel Treatments with Small Molecules in Psoriatic Arthritis
- (2014) Renata Baronaite Hansen et al. Current Rheumatology Reports
- The new era for the treatment of psoriasis and psoriatic arthritis: Perspectives and validated strategies
- (2013) Lucia Novelli et al. AUTOIMMUNITY REVIEWS
- Systemic methotrexate therapy for psoriasis: past, present and future
- (2013) S. Dogra et al. CLINICAL AND EXPERIMENTAL DERMATOLOGY
- Major cardiovascular events associated with anti-IL 12/23 agents: A tale of two meta-analyses
- (2013) Erica D. Dommasch et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Regulation of metabolism by cGMP
- (2013) Alexander Pfeifer et al. PHARMACOLOGY & THERAPEUTICS
- Cyclosporine Regimens in Plaque Psoriasis: An Overview with Special Emphasis on Dose, Duration, and Old and New Treatment Approaches
- (2013) M. D. Colombo et al. TheScientificWorldJOURNAL
- Apremilast mechanism of action and application to psoriasis and psoriatic arthritis
- (2012) Peter Schafer BIOCHEMICAL PHARMACOLOGY
- Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study
- (2012) K.A. Papp et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial
- (2012) Kim Papp et al. LANCET
- Disposition, metabolism and mass balance of [14C]apremilast following oral administration
- (2011) Matthew Hoffmann et al. XENOBIOTICA
- Definition of treatment goals for moderate to severe psoriasis: a European consensus
- (2010) U. Mrowietz et al. ARCHIVES OF DERMATOLOGICAL RESEARCH
- Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents
- (2010) Wolfgang Weger BRITISH JOURNAL OF PHARMACOLOGY
- Integrative Responses to IL-17 and TNF-α in Human Keratinocytes Account for Key Inflammatory Pathogenic Circuits in Psoriasis
- (2010) Andrea Chiricozzi et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases
- (2010) Georg Schett et al. Therapeutic Advances in Musculoskeletal Disease
- Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis
- (2009) PH Schafer et al. BRITISH JOURNAL OF PHARMACOLOGY
- Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis
- (2009) Vinod Chandran et al. JOURNAL OF AUTOIMMUNITY
- Discovery of (S)-N-{2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamide (Apremilast), a Potent and Orally Active Phosphodiesterase 4 and Tumor Necrosis Factor-α Inhibitor
- (2009) Hon-Wah Man et al. JOURNAL OF MEDICINAL CHEMISTRY
- Guidelines of care for the management of psoriasis and psoriatic arthritis
- (2009) Alan Menter et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Psoriasis
- (2009) Frank O. Nestle et al. NEW ENGLAND JOURNAL OF MEDICINE
- An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast
- (2008) A. B. Gottlieb et al. CURRENT MEDICAL RESEARCH AND OPINION
- Guidelines of care for the management of psoriasis and psoriatic arthritis
- (2008) Alan Menter et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Targeting signaling pathways with small molecules to treat autoimmune disorders
- (2007) Bozena Kaminska et al. Expert Review of Clinical Immunology
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started